Role of NLRP3 inflammasome in systemic sclerosis

Table 2 Inhibitors of NLRP3 inflammasome in SSc therapy

Inhibitor	Target	Evidence	Reference
MCC950(CP-456,773)	NLRP3	Prevents IL-1β excretion, impeding myofibroblast transition and pulmonary fibrosis	[111]
		Reduces inflammation and liver fibrosis	[112]
		Reduces immune cell infiltration and myocardial fibrosis	[113]
		Reduces immune cell infiltration and collagen production in kidney	[114]
CY-09	NLRP3	Reduces ischemia-induced myocardial fibrosis	[117]
A20 (TNFAIP3)	NLRP3	Prevents pulmonary fibrosis	[118]
A20 (TNFAIP3)	NLRP3	Reduces NLRP3-mediated cytokine secretion and pyroptosis in RA	[104]
BHB	NLRP3	Reduces caspase-1 maturation and IL-1β secretion	[119]
YVAD-CHO	Caspase-1	Reduces IL-1β excretion in SSc monocytes	[120]
Z-YVAD-FMK	Caspase-1	Eliminates oversecretion of IL-1β in fibroblasts from skin and lung of SSc patients	[62]
Anakinra	IL-1R	Alleviates BLM-induced inflammation and pulmonary fibrosis	[121]
Anakinra	IL-1R	Improves vascular function in RA patients	[122]

Abbreviations: SSc systemic sclerosis, IL interleukin, RA rheumatoid arthritis, BHB β-hydroxybutyrate

ISSN: 1478-6362